Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis,

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Pulmonary exacerbations in CF patients with early lung disease

Safety and early treatment effects of the CXCR2 antagonist SB in patients with cystic fibrosis Richard B. Moss, Sunil J. Mistry, Michael W. Konstan,

Controlled clinical trials in cystic fibrosis — are we doing better?

Inhaled aztreonam lysine vs

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis Diana Bilton, Gabriel Bellon, Brett Charlton, Peter Cooper,

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Eradication of early P. aeruginosa infection in children

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis Kavi J. Littlewood, Kyoko Higashi,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients Gregory S. Sawicki, Will Chou, Karina.

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Cystic fibrosis and pregnancy in the modern era: A case control study

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias Kappler, Raphaël Chiron, Mark Higgins, Florian Brockhaus, Jie Zhang, Gerhild Angyalosi, Ellie He, David E. Geller Journal of Cystic Fibrosis Volume 10, Issue 1, Pages 54-61 (January 2011) DOI: 10.1016/j.jcf.2010.10.003 Copyright © 2010 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Study design (A) and disposition (B). Journal of Cystic Fibrosis 2011 10, 54-61DOI: (10.1016/j.jcf.2010.10.003) Copyright © 2010 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Overall efficacy: A) relative change in FEV1% predicted from baseline over three cycles (efficacy population); and B) change from baseline in Pseudomonas aeruginosa sputum density (efficacy population). Journal of Cystic Fibrosis 2011 10, 54-61DOI: (10.1016/j.jcf.2010.10.003) Copyright © 2010 European Cystic Fibrosis Society. Terms and Conditions